NPPA Fixes Retail Prices of 42 Drug Formulations Under DPCO 2013 in India

NPPA Fixes Retail Prices of 42 Drug Formulations Under DPCO 2013 in India

Introduction 

The National Pharmaceutical Pricing Authority (NPPA) has released a new retail price notification under the Drugs Price Control Order (DPCO) 2013, fixing the retail prices of 42 pharmaceutical formulations in India. The latest NPPA notification 2026 was issued on April 30, 2026, by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers.

The updated medicine price list includes drugs used for diabetes, cardiac care, infections, pain relief, respiratory disorders, and vitamin deficiencies. The move aims to regulate medicine pricing, improve affordability, and ensure better access to essential medicines across India.

The new NPPA drug price notification includes formulations such as Atorvastatin combinations, Cefixime tablets, Metformin medicines, Vitamin D3 oral solution, and respiratory drugs. Under DPCO 2013, pharmaceutical companies must comply with the revised retail prices fixed by the drug pricing authority in India.

What Is the NPPA Retail Price Notification?

The NPPA retail price notification is an official order issued by the National Pharmaceutical Pricing Authority (NPPA) under the Drugs Price Control Order (DPCO) 2013 to fix or revise the retail prices of medicines in India. Under this notification, pharmaceutical companies must sell the listed formulations at the approved retail prices.

The latest NPPA notification 2026 includes several commonly prescribed medicines used for diabetes, cardiac care, infections, pain relief, and vitamin deficiencies. The updated medicine price list India aims to improve affordability and ensure price regulation in the pharmaceutical sector.

The newly notified formulations include:

• Atorvastatin & Ezetimibe Tablets
• Cefixime & Potassium Clavulanate Tablets
• Gliclazide & Metformin Hydrochloride Tablets
• Telmisartan Combination Tablets
• Vitamin D3 Oral Solution
• Paracetamol Combination Medicines

The new drug price notification released under DPCO 2013 is important for pharmaceutical manufacturers, healthcare professionals, retailers, and patients across India.

Why Is NPPA Fixing Medicine Prices in India?

The National Pharmaceutical Pricing Authority (NPPA) regulates medicine prices in India to ensure essential medicines remain affordable and accessible for patients. Under the Drugs Price Control Order (DPCO) 2013, the NPPA has the authority to fix and revise the retail prices of scheduled medicines and certain new drug formulations.

The latest NPPA drug price notification is aimed at improving price regulation and maintaining transparency in the Indian pharmaceutical sector. By controlling medicine pricing, the government helps protect consumers from unreasonable price increases and supports affordable healthcare access across India.

This medicine price regulation process helps to:

• Prevent excessive pricing of essential medicines
• Improve medicine accessibility in India
• Support affordable healthcare for patients
• Ensure transparency in pharmaceutical pricing
• Strengthen drug price regulation under DPCO 2013

The NPPA retail price notification also ensures that pharmaceutical companies comply with government-approved pricing while marketing medicines in India.

Important Compliance Rules for Pharma Companies

According to the latest NPPA retail price notification, pharmaceutical manufacturers must issue updated price lists and comply with the retail prices fixed under DPCO 2013. Companies are required to follow the approved pricing while marketing medicines in India.

Under the new NPPA drug price notification, retailers and dealers must also display the revised medicine price list at their business premises to ensure transparency for consumers and healthcare providers.

Failure to comply with the notified retail prices may lead to regulatory action under the Essential Commodities Act, 1955 and the provisions of DPCO 2013.

Conclusion

The latest NPPA retail price notification April 2026 reflects the government’s continued efforts to regulate medicine prices and improve healthcare affordability in India. Under DPCO 2013, the revised retail prices of 42 pharmaceutical formulations are aimed at ensuring better access to essential medicines for patients across the country.

The updated NPPA drug price notification includes medicines used for cardiac care, diabetes, infections, respiratory diseases, pain management, and nutritional supplements. The revised medicine price list India is expected to support pricing transparency, strengthen pharmaceutical regulation, and improve accessibility in the healthcare sector.

The notification is an important development for pharmaceutical companies, healthcare professionals, retailers, and consumers following the latest updates in the Indian pharmaceutical industry.

Access the latest NPPA retail price notification and updated medicine price list under DPCO 2013.

Note:
Cases related to Pharmaceuticals are highly technical and knowledge-driven. If you're searching for a drugs and cosmetics lawyer in India, a pharmaceutical lawyer, Mace Corporate Associates is the perfect place. If you are searching for a DPCO Lawyer for overcharging cases or DPCO Compliance, Mace can assist you well. May it be a clinical trial Lawyer or a Medical device lawyer, Mace can be of great and perfect match for Pharmaceutical litigation. Mace has an accomplished track record for Not of Standard Quality Cases, Licensing Cases etc.